Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: Differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells

Infection and Immunity

Volumn 67, Issue 12, 1999, Pages 6270-6280

  Ryan, Elizabeth J ^a   Mcneela, Edel ^a   Murphy, Geraldine A ^a   Stewart, Helen ^a   O'Hagan, Derek ^b   Pizza, Mariagrazia ^c   Rappuoli, Rino ^c   Mills, Kingston H G ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c CHIRON VACCINES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ALUMINUM POTASSIUM SULFATE; BACTERIAL TOXIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PERTUSSIS VACCINE;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACTERIUM MUTANT; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; ESCHERICHIA COLI; FEMALE; HELPER CELL; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANESTHESIA; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL TOXINS; BORDETELLA PERTUSSIS; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FEMALE; IMMUNITY, MUCOSAL; IMMUNIZATION; MICE; MICE, INBRED BALB C; MUTATION; PERTUSSIS VACCINE; T-LYMPHOCYTES, HELPER-INDUCER; TH1 CELLS; TH2 CELLS; WHOOPING COUGH;

EID: 0032728547     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Almeida, A. J., and H. O. Alpar. 1996. Nasal delivery of vaccines. J. Drug Targeting 3:455-467.
2. Barbic, J., M. F. Leef, D. L Burns, and R. D. Shahin. 1997. Role of gamma interferon in natural clearance of Bordetella pertussis respiratory infection. Infect. Immun. 65:4904-4908.
3. Braun, M. C., J. He, C. Y. Wu, and B. Kelsall. 1999. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor β1 and β2 chain expression. J. Exp. Med. 189:541-552.
4. Cahill, E. S., D. T. O'Hagan, L. Illum, A. Barnard, K. H. G. Mills, and K. Redhead. 1995. Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. Vaccine 13:455-462.
5. Cahill, E. S., D. T. O'Hagan, L. Illum, and K. Redhead. 1993. Mice are protected against Bordetella pertussis infection by intra-nasal immunization with filamentous haemagglutinin. FEMS Microhiol. Lett. 107:211-216.
6. Centers for Disease Control and Prevention. 1997. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Weekly Rep. 46:RR1-RR25.
7. deHaan, L., L. K. Feil, W. R. Verweij, M. Holtrop, W. G. J. Hol, E. Agsteribbe, and J. Wilschut. 1998. Mutational analysis of the role of ADP-ribosylation activity and GM1-binding activity in the adjuvant properties of the Escherichia coli heat-labile enterotoxin towards intranasally administered keyhole limpet hemocyanin. Eur. J. Immunol. 28:1243-1250.
8. deHaan, L., M. Holtrop, W. R. Verweij, E. Agsteribbe, and J. Wilschut. 1996. Mucosal immunogenicity of the Escherichia coli heat-labile enterotoxin: role of the A-subunit. Vaccine 14:260-266.
9. Dickinson, B. L., and J. D. Clements. 1995. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63:1617-1623.
10. Douce, G., C. Turcotte, L. Cropley, M. Roberts, M. Pizza, M. Domenghini, R. Rappuoli, and G. Dougan. 1995. Mutants of Escherichia coli heat labile toxin lacking ADP-ribosyltransferase activity act as non-toxic mucosal adjuvants. Proc. Natl. Acad. Sci. USA 92:1644-1548.
11. Douce, G., M. M. Giuliani, V. Giannelli, M. Pizza, R. Rappuoli, and G. Dougan. 1998. Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli. Vaccine 16:1065-1073.
12. Frieke Kuper, C., P. J. Koornstra, D. M. H. Hameleers, J. Biewenga, B. J. Spit, A. M. Duijvestijn, P. J. C. van Breda Vriesman, and T. Sminia. 1992. The role of nasopharyngeal lymphoid tissue. Immunol. Today 13:219-224.
13. Giuliani, M. M., G. Del Giudice, V. Giannelli, G. Dougan, G. Douce, R. Rappuoli, and M. Pizza. 1998. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile toxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 187:1123-1132.
14. Greco, D., S. Salmaso, P. Mastrantonio, M. Guiliano, A. G. Tozzi, A. Anemona, M. L. Giori Delgi Atti, A. Giammanco, P. Panel, W. C. Blackwelder, D. L. Klein, S. G. F. Wassilak, and the Progetto Pertosase Working Group. 1996. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med. 334:341-347.
15. Gustafsson, L., H. O. Hallander, P. Olin, E. Reizenstein, and J. Storsaeter. 1996. A controlled trial of a two-component acellular, a five-component acellular and a whole cell pertussis vaccine. N. Engl. J. Med. 334:349-355.
16. Jones, D. H., B. W. McBride, C. Thornton, D. T. O'Hagan, A. Robinson, and G. H. Farrar. 1996. Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection. Infect. Immun. 64:489-494.
17. Lycke, N., T. Tsuji, and J. Holmgren. 1992. The adjuvant effect of Vibrio cholerae and Escherichia coli heat labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 22:2277-2281.
18. Mahon, B. P., M. S. Ryan, F. Griffin, and K. H. G. Mills. 1996. Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting the induction of Th1 cells. Infect. Immun. 64:5295-5301.
19. Mahon, B. P., B. J. Sheahan, F. Griffin, G. Murphy, and K. H. G. Mills. 1997. Atypical disease after Bordetella pertussis respiratory infection of mice with targeted disruptions of interferon-γ receptor or immunoglobulin μ chain genes. J. Exp. Med. 186:1843-1851.
20. Marinaro, M., H. F. Staats, T. Hiroi, R. J. Jackson, M. Coste, P. N. Boyaka, N. Okahashi, M. Yamamoto, H. Kiyono, H. Bluethmann, K. Fujihashi, and J. R. McGhee. 1995. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 155:4621-4629.
21. Mills, K. H. G., M. Ryan, E. Ryan, and B. P. Mahon. 1998. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect. Immun. 66:594-602.
22. Mills, K. H. G., A. Barnard, J. Watkins, and K. Redhead. 1993. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect. Immun. 61:399-410.
23. Munoz, E., A. M. Zubiaga, M. Merrow, N. P. Sauter, and B. T. Huber. 1990. Cholera toxin discriminated between T helper 1 and 2 cells in T cell receptor-mediated activation: role of cAMP in T cell proliferation. J. Exp. Med. 172:95-103.
24. Pizov, R., M. Takahashi, C. A. Hirshman, and T. Croxton. 1992. Halothane inhibition of ion transport of the tracheal epithelium. A possible mechanism for the anesthetic-induced impairment of mucociliary clearance. Anesthesiology 76:985-989.
25. Podda, A., L. Nencioni, I. Marsili, S. Peppoloni, G. Volpini, D. Donati, A. DiTommaso, M. T. DeMagistris, and R. Rappuoli. 1991. Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa. Vaccine 9:741-745.
26. Porro, M., M. Saletti, L. Nencioni, L. Tagliaferri, and I. Marsili. 1980. Immunogenic correlation between cross-reacting material (CRM-197) produced by a mutant of Corynebacterium diphtheriae and diphtheria toxoid. J. Infect. Dis. 142:716-724.
27. Rappuoll, R., M. Pizza, A. Podda, M. T. De Magistris, and L. Nencioni. 1991. Towards third generation whooping cough vaccines. Trends Biotechnol. 9:232-238.
28. Redhead, K., J. Watkins, A. Barnard, and K. H. G. Mills. 1993. Effective immunization against Bordetella pertussis infection in mice is dependent on the induction of cell-mediated immunity. Infect. Immun. 61:3190-3198.
29. Roberts, M., A. Bacon, R. Rappuoli, M. Pizza, L. Cropley, G. Douce, G. Dougan, M. Marinaro, J. McGhee, and S. Chatfield. 1995. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/ 129G, is an effective mucosal adjuvant for intranasally delivered proteins. Infect. Immun. 63:2100-2108.
30. Ryan, E., and K. H. G. Mills. Unpublished data.
31. Ryan, M., L. McCarthy, R. Rappuoli, B. P. Mahon, and K. H. G. Mills. 1998. Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the costimulatory molecules B7-1, B7-2 and CD28. Int. Immunol. 10:651-662.
32. Ryan, M., G. Murphy, E. Ryan, L. Nilsson, F. Shackley, L. Gothefors, K. Oymar, E. Miller, J. Storsaeter, and K. H. Mills. 1998. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 93:1-10.
33. Shahin, R. D., M. Leef, J. Eldridge, M. Hudson, and R. Gilley. 1995. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-Co-glycolide) microspheres. Infect. Immun. 63:1195-1200.
34. 2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J. Immunol. 150:5321-5329.
35. Takahashi, I., M. Marinaro, H. Kiyono, R. J. Jackson, L. Nakagawa, K. Fujihashi, S. Hamada, J. D. Clements, K. L. Bost, and J. R. McGhee. 1996. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J. Infect. Dis. 173:627-635.
36. Thompson, A. H., J. G. McRoberts, S. R. Crowe, L. London, and S. D. London. 1999. Optimal induction of upper respiratory tract immunity to reovirus 1/L by combined upper and lower respiratory tract inoculation. Vaccine 17:1404-1415.
37. Walker, R I. 1994. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 12:387-399.
38. Williams, N. A., T. R. Hirst, and T. O. Nashar. 1999. Immune modulation by cholera-like enterotoxins: from adjuvant to therapeutic. Immunol. Today. 20:95-101.